News Conference News ACC 2025 ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a) L.A. McKeown April 10, 2025
News Conference News ACC 2025 FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints L.A. McKeown April 03, 2025
News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
Presentation ACC 2025 STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes Presenter: Marc P. Bonaca March 29, 2025
Presentation ACC 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Presenter: Darren K. McGuire March 29, 2025
News Daily News ACC 2025 STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients L.A. McKeown March 29, 2025